U.S. markets close in 5 hours 54 minutes
  • S&P 500

    4,149.57
    +7.98 (+0.19%)
     
  • Dow 30

    33,858.42
    +181.15 (+0.54%)
     
  • Nasdaq

    14,027.26
    +31.17 (+0.22%)
     
  • Russell 2000

    2,254.01
    +25.09 (+1.13%)
     
  • Crude Oil

    61.53
    +1.35 (+2.24%)
     
  • Gold

    1,737.40
    -10.20 (-0.58%)
     
  • Silver

    25.34
    -0.08 (-0.32%)
     
  • EUR/USD

    1.1963
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    1.6410
    +0.0180 (+1.11%)
     
  • GBP/USD

    1.3778
    +0.0026 (+0.19%)
     
  • USD/JPY

    109.0220
    -0.0260 (-0.02%)
     
  • BTC-USD

    63,700.52
    +784.77 (+1.25%)
     
  • CMC Crypto 200

    1,367.49
    -8.28 (-0.60%)
     
  • FTSE 100

    6,922.78
    +32.29 (+0.47%)
     
  • Nikkei 225

    29,620.99
    +82.29 (+0.28%)
     

Autolus Therapeutics PLC Sponsored ADR (AUTL) Surges 6.5%: Is This an Indication of Further Gains?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Autolus Therapeutics PLC Sponsored ADR (AUTL) shares ended the last trading session 6.5% higher at $6.86. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.7% loss over the past four weeks.

2021 and 2022 are expected to be catalyst-rich years for Autolus with several data read-outs from its next-generation programmed T cell therapies to be presented in these two years. Increased optimism surrounding the data-reaouts has been driving the stock price higher.

Price and Consensus

Price Consensus Chart for Autolus Therapeutics PLC Sponsored ADR
Price Consensus Chart for Autolus Therapeutics PLC Sponsored ADR

This company is expected to post quarterly loss of $0.75 per share in its upcoming report, which represents a year-over-year change of +19.4%. Revenues are expected to be $0.43 million, up 37.1% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Autolus Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUTL going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Autolus Therapeutics PLC Sponsored ADR (AUTL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research